双鹭药业(002038) - 2020 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2020 was ¥194,660,284.30, a decrease of 58.19% compared to ¥465,621,600.26 in the same period last year[10] - Net profit attributable to shareholders was ¥61,582,818.21, down 69.29% from ¥200,556,922.20 year-on-year[10] - The net profit after deducting non-recurring gains and losses was ¥42,821,601.46, representing a 76.56% decline from ¥182,654,917.90 in the previous year[10] - Basic and diluted earnings per share were both ¥0.0599, down 79.54% from ¥0.2928 year-on-year[10] - The company's operating income for the current period is approximately ¥66.46 million, a decrease from ¥224.92 million in the previous period, reflecting a decline of about 70.5%[61] - The net profit attributable to the parent company is approximately ¥61.58 million, down from ¥200.56 million, representing a decrease of about 69.3%[61] - The total comprehensive income for the current period is approximately ¥66.76 million, compared to ¥195.47 million in the previous period, indicating a decline of about 65.8%[65] Cash Flow - The net cash flow from operating activities increased by 37.23% to ¥665,826,611.98, compared to ¥485,173,510.50 in the same period last year[10] - Cash inflow from operating activities is approximately ¥2.38 billion, a slight decrease from ¥2.34 billion in the previous period, reflecting a decline of about 0.7%[73] - The total cash inflow from operating activities was 2,312,159,811.07, down 3.2% from 2,388,054,836.75 in the previous period[80] - Total cash outflow from operating activities was 1,711,881,607.63, down 11% from 1,922,612,462.72 in the previous period[76] - The ending balance of cash and cash equivalents was 1,250,109,126.93, an increase from 1,166,197,875.47 in the previous period[78] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,307,454,317.56, an increase of 1.58% from ¥5,224,966,177.85 at the end of the previous year[10] - The total current assets as of March 31, 2020, amounted to ¥2,485,103,661.76, down from ¥2,865,341,706.18 at the end of 2019, indicating a decrease of approximately 13.27%[39] - The company's total liabilities decreased from ¥403,757,007.80 to ¥376,308,179.66, a reduction of approximately 6.8%[45] - The total liabilities amounted to CNY 270,728,873.86, a decrease from CNY 286,248,984.20, indicating improved financial stability[55] Shareholder Information - Net assets attributable to shareholders increased by 2.29% to ¥4,918,282,636.75 from ¥4,808,196,812.66 at the end of the previous year[10] - The top ten shareholders held a total of 55,090 shares, with the largest shareholder, Xu Mingbo, owning 22.58% of the shares[15] - The total equity attributable to shareholders increased to CNY 4,893,863,151.88 from CNY 4,833,935,997.11, showing a growth in shareholder value[55] Research and Development - Research and development expenses increased to CNY 28,032,869.66, compared to CNY 22,397,212.53 in the previous year, indicating a focus on innovation[58] - Research and development expenses increased to approximately ¥152.81 million from ¥76.27 million, representing an increase of about 100.5%[66] - The company aims to expand its market presence and enhance product offerings through ongoing research and development efforts[58] Government Support - The company received government subsidies amounting to ¥4,006,392.86 during the reporting period[10] Investment Activities - The company's long-term equity investments increased from ¥408,680,545.37 to ¥900,375,039.94, representing a growth of approximately 120%[41] - The company has a long-term investment of CNY 1,098,182,823.28, significantly higher than CNY 603,500,618.95 from the previous year, suggesting strategic growth initiatives[52] Other Financial Information - The company's inventory increased from ¥108,345,829.53 to ¥163,199,389.95, marking an increase of about 50.73%[39] - The company reported no overdue commitments from actual controllers, shareholders, or related parties during the reporting period[27] - The company has not engaged in any derivative investments during the reporting period[32] - There were no significant or high-risk entrusted financial management situations reported during the period[31]